Cardiovascular diseases lead to 31.5% of deaths globally, and particularly myocardial infarction (MI) results in 7.4 million deaths per year. Diagnosis of MI and monitoring for prognostic use are critical for clinical management and biomedical research, which require advanced tools with accuracy and speed. Herein, we developed a plasmonic gold nano-island (pGold) chip assay for diagnosis and monitoring of MI. On-chip microarray analysis of serum biomarkers (e.g., cardiac troponin I) afforded up to 130-fold enhancement of near-infrared fluorescence for ultra-sensitive and quantitative detection within controlled periods, using 10 μL of serum only. The pGold chip assay achieved MI diagnostic sensitivity of 100% and specificity of 95.54%, superior to the standard chemiluminescence immunoassay in cardiovascular clinics. Further, we monitored biomarker concentrations regarding percutaneous coronary intervention for prognostic purpose. Our work demonstrated a designed approach using plasmonic materials for enhanced diagnosis and monitoring for prognostic use towards point-of-care testing.

心血管疾病导致全球31.5％的死亡，尤其是心肌梗塞（MI）每年导致740万人死亡。MI的诊断和用于预后的监测对于临床管理和生物医学研究至关重要，这需要具有准确性和速度的先进工具。在本文中，我们开发了一种等离子金纳米岛（pGold）芯片测定法，用于诊断和监测MI。仅使用10μL血清，对血清生物标志物（例如，心肌肌钙蛋白I）进行的芯片微阵列分析可在控制时间内对近红外荧光进行多达130倍的超灵敏和定量检测。pGold芯片检测的MI诊断灵敏度为100％，特异性为95.54％，优于心血管诊所的标准化学发光免疫检测。进一步，我们监测了经皮冠状动脉介入治疗的生物标志物浓度，以进行预后评估。我们的工作展示了一种设计的方法，该方法使用等离子材料来增强诊断和监测，以用于对即时检验的预后。